MARKET NEWS

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients With Pre-existing Antibodies to AAV5 Vector
Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate 
Advicenne Receives Positive Feedback From US FDA on Pathway to Approval & Amended Phase 3 Study Protocol
BD to Build New Manufacturing Facility in Spain to Support Ongoing Strong Growth of Prefilled Drug Delivery Business
NovAliX Expands Cryo-Electron Microscopy Capabilities for Drug Development Offering
AC Immune Announces Expansion of Phase 1b/2a Phospho-Tau Alzheimer’s Vaccine Trial & Provides a Program Update

  FEATURED EDITORIAL

  COMPANY PROFILE

For over 30 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation & Sustainability in Digital Drug Delivery

Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation & Sustainability in Digital Drug Delivery

Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic, and MedTech devices, recently unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market….

Biogen & Envisagenics Announce Collaboration to Advance RNA Splicing Research

Biogen & Envisagenics Announce Collaboration to Advance RNA Splicing Research

Biogen Inc. and Envisagenics recently announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases….

Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial

Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial

Mustang Bio, Inc. and City of Hope recently announced the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (eg, glioblastoma, ependymoma, or medulloblastoma). The trial will enroll up to 30 patients and is taking place at City of Hope, where this chimeric antigen receptor T (CAR T) cell therapy was initially developed. Even though it is a single center clinical trial,

 » Read more about: Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial  »

Calithera Biosciences & Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

Calithera Biosciences & Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

Calithera Biosciences, Inc. and Antengene Corporation, Ltd. recently announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera’s small….

Agenus & Bristol Myers Squibb Announce Exclusive Global License for Anti-TIGIT Bispecific Antibody Program

Agenus & Bristol Myers Squibb Announce Exclusive Global License for Anti-TIGIT Bispecific Antibody Program

Bristol-Myers Squibb Company and Agenus Inc. recently announced they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 2 – Capsules
June 9 – Injection Devices